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Ottawa, Canada
Objectives We sought to examine the short-term and longer term (6-week) effects of continuous positive airway pressure
(CPAP) on myocardial energetics.
Background Obstructive sleep apnea (OSA) and heart failure (HF) are both states of increased afterload and metabolic demand.
Treatment with CPAP may initially reduce stroke volume but subsequently improves left ventricular function. However,
it is not clear whether CPAP therapy favorably affects myocardial energetics and hence improves cardiac efficiency.
Methods Twelve patients with HF were divided into two groups: 7 patients with OSA were treated with CPAP (group I), and
5 patients without OSA served as a control group (group II). Oxidative metabolism was measured using the
mono-exponential fit of the myocardial [11C] acetate positron emission tomography time-activity curve (k-mono).
Myocardial efficiency was derived using the work metabolic index (WMI [heart rate  stroke volume index  sys-
tolic blood pressure]/k-mono) measured at baseline, during short-term CPAP, and after 6 3 weeks of CPAP.
Results In group I, short-term CPAP tended to reduce SVI (p  0.063) and reduced oxidative metabolism (p  0.031).
Work metabolic index did not change. However, longer term CPAP improved left ventricular ejection fraction
(38.4  3.3% to 43.4  4.8%, p  0.031), tended to reduce oxidative metabolism (0.047  0.012 to 0.040 
0.008 min1, p  0.078), and improved WMI (7.13  2.82  106 to 8.17  3.06  106 mm Hg·ml/m2, p 
0.031). In group II (control), these parameters did not change.
Conclusions In this cohort of patients with HF and OSA, short-term CPAP decreased oxidative metabolism and tended to de-
crease SVI, but did not alter cardiac efficiency. Longer term CPAP improved cardiac efficiency, indicating an
energy-sparing effect. These effects may contribute to the benefits of CPAP therapy. (J Am Coll Cardiol 2007;
49:450–8) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.059(
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Morbidity, mortality, and hospitalization rates for
heart failure (HF) remain high despite advances
in pharmacologic therapy (1). Sleep-related
breathing disorders, including obstructive sleep
apnea (OSA), often coexist with HF and may
contribute to disease progression (2–4).
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ugust 28, 2006.Heart failure is characterized by an energy-depleted state
5). High wall stress from increased afterload increases
etabolic demand at the expense of forward kinetic work.
See page 459
ncreased metabolic demand (myocardial oxygen consump-
ion [MVO2] and oxidative metabolism) associated with
mpaired ventricular function indicates a reduced myocar-
ial efficiency that is characteristic of HF (6–8) and
orrelates with a poor prognosis (8).
Repeated apnea-arousal cycles that characterize OSA lead
o altered loading conditions, hypoxia, and sympathetic ner-
ous system activation (2,4,9). These changes during sleep, and
he “carryover” daytime effects, may increase metabolic demand
n the myocardium, further altering cardiac energetics (2,4,9).
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January 30, 2007:450–8 Effects of CPAP on Myocardial EnergeticsContinuous positive airway pressure (CPAP) therapy has
een shown to reduce sympathetic nervous system activa-
ion, preload, and afterload in the short-term or longer term
etting (2,4). Small studies in OSA and HF patients have
emonstrated that 1 to 3 months of CPAP therapy im-
roves left ventricular (LV) systolic function (10–12). How-
ver, the mechanisms for the therapeutic effect of CPAP in
atients with OSA and HF remain uncertain (2).
[11C] acetate positron emission tomography (PET) pro-
ides a non-invasive technique for measuring regional and
lobal myocardial oxidative metabolism (6,13–16), which is
losely correlated with tricarboxylic acid cycle flux and
VO2 (13,14). Combined with an assessment of cardiac
unction, [11C] acetate PET can be applied as a noninvasive
pproach to study myocardial energetics and efficiency in
ivo (6,15,16).
Therapies that improve LV function at the expense of
VO2 or oxidative metabolism (thus reducing efficiency)
re associated with poorer outcomes (5). In contrast, after-
oad reduction and beta-blocker therapy, which improve
fficiency, are associated with improved patient outcomes
17). Therapy with CPAP appears to improve LV systolic
unction, but its effects on oxidative metabolism and effi-
iency in patients with HF and OSA are not known.
The primary aim of this study was to evaluate the daytime
arryover effect of longer term (6-week) nocturnal CPAP
herapy on cardiac metabolism and efficiency using [11C]
cetate PET. The secondary aim was to evaluate the effect
f short-term CPAP application on cardiac metabolism and
fficiency.
ethods
tudy subjects. Study subjects were recruited from the HF
linic of the University of Ottawa Heart Institute. The
atient inclusion criteria were: 1) LV systolic dysfunction
left ventricular ejection fraction [LVEF] 40%), 2) symp-
oms of HF: New York Heart Association functional class
I or III, and 3) stable condition (unchanged for4 weeks).
Exclusion criteria included unstable angina or recent MI
4 weeks), severe valvular heart disease, permanent pace-
aker, and significant restrictive or obstructive lung disease.
The study was approved by the University of Ottawa
eart Institute Human Research Ethics Board. Written
nformed consent was obtained from all patients.
xperimental protocol. Thirteen HF patients underwent
vernight polysomnography to assess for the presence of
SA. Obstructive sleep apnea was diagnosed on nocturnal
olysomnography and defined as an apnea/hypopnea index
AHI) 15 (3,18) events/h of sleep (more than 80% of
pnea/hypopnea events being obstructive in nature). Pa-
ients with the AHI 10 and no indication for CPAP
herapy served as a control group.
All patients underwent baseline measurements, including
chocardiography and [11C] acetate PET, at rest while
wake. Patients with OSA and HF had baseline studies wepeated during awake applica-
ion of short-term CPAP at the
ressure determined from the
PAP titration study (discussed
n the later text). Echocardiogra-
hy was repeated 45 min after
nitiating the therapeutic pres-
ure of CPAP (19) (mean pres-
ure 10.6  1.6 cm H2O) and
ollowed immediately by [11C]
cetate PET.
Subsequently, patients with
F and OSA were treated at
ome with nightly nocturnal na-
al CPAP therapy. Echocardiog-
aphy and [11C] acetate PET
ere repeated after 6  3 weeks
f nocturnal CPAP therapy
mean pressure 10.6  1.6 cm
2O).
Patients with HF but without
SA served as the control group
nd underwent echocardiography and [11C] acetate PET at
est at baseline and after 9  6 weeks (p  NS).
leep studies. A single overnight polysomnogram was
erformed using the Alice system (Respironics, Aria LX;
ittsburgh, Pennsylvania). Sleep staging was determined
sing Rechtschaffen and Kale’s criteria (20). An obstructive
pnea was defined as cessation of airflow for 10 s with
ersistent respiratory effort as seen in the ribcage or abdo-
en signals; hypopnea was defined as a decrease in airflow,
ibcage, or abdominal motion by 50% of the baseline
ignal for10 s with a4% fall in O2 saturation. The AHI
as the total number of apneas and hypopneas per hour of
leep. Obstructive sleep apnea was defined by AHI 15/h
2,4,18) and 80% of all apnea/hypopnea events had to be
bstructive for inclusion.
PAP titration and therapy. Patients assigned to CPAP
ad a CPAP titration sleep study to determine the appro-
riate CPAP pressure 7 days before baseline PET and
chocardiography. After all baseline studies were completed,
atients were instructed to use the CPAP device (ResMed
7 Elite, ResMed Corp., San Diego, California) every
ight. Compliance with CPAP was assessed on the day of
ollow-up assessment using built-in hour meters in the
PAP machines (10). The control patients were not treated
ith CPAP.
chocardiography. Ventricular function was assessed by
-dimensional echocardiography using a Sonos 5500 ultra-
ound system (Phillips, Andover, Massachusetts) equipped
ith a 3.2-MHz phased-array transducer. Forward stroke
olume (SV) was derived from the velocity-time integral of
he pulsed Doppler LV outflow tract velocity signal and the
V outflow tract diameter (21). Stroke volume index (SVI)
Abbreviations
and Acronyms
AHI  apnea/hypopnea
index
CPAP  continuous
positive airway pressure
HF  heart failure
LV  left
ventricle/ventricular
LVEF  left ventricular
ejection fraction
MVO2  myocardial oxygen
consumption
OSA  obstructive sleep
apnea
PET  positron emission
tomography
SVI  stroke volume index
WMI  work metabolic
indexas derived by dividing SV by the body surface area.
P
w
S
(
s
b
i
[
n
i
t
w
c
p
p
i
d
A
c
t
b
W
s
S
k
c
m
t
c
S
m
p
o
t
t
c
a
w
a
i
p
c
v
d
S
N
R
P
452 Yoshinaga et al. JACC Vol. 49, No. 4, 2007
Effects of CPAP on Myocardial Energetics January 30, 2007:450–8ET. Immediately following echocardiography, patients
ere positioned in a quiet and awake state in the
iemens/CTI ART PET scanner (Knoxville, Tennessee)
16). A dynamic PET acquisition was initiated (10 10
; 2  30 s; 5  100 s; 3 180 s; 2  300 s), followed
y administration of 10 mCi (370 MBq) [11C] acetate
ntravenously.
11C] acetate PET data analysis. The reconstructed dy-
amic PET images were analyzed by applying a region of
nterest over the whole LV myocardium in 3 to 5 midven-
ricular transaxial planes (16). A mono-exponential function
as fit to the myocardial time activity data, and the
learance rate constant (kmono) was determined as described
reviously (6,22). The mono-exponential fit begins at the
oint when the blood pool is stable (usually 2 to 4 min after
njection) (Fig. 1).
All data were analyzed blind to the clinical and imaging
ata and to the OSA status.
ssessment of myocardial efficiency. The [11C] acetate
learance data were combined with the stroke work data
o derive myocardial efficiency using the LV work meta-
olic index (WMI), as described previously (6,15,16):
MI  SVI  SBP  HR/kmono; where SVI is the
troke volume index determined by echocardiography,
BP is systolic blood pressure, HR is heart rate, and
Figure 1 Example of Myocardial Time-Activity Data From an 11C
A monoexponential function fit to the myocardial clearance yields a clearance rate
kmono represents the rate of oxidative metabolism and reflects myocardial oxygenmono is the mono-exponential rate constant for C-11 tlearance from the myocardium. This equation is a
odification of the minute-work-to-oxygen consump-
ion relationship originally defined as mechanical effi-
iency (7).
tatistical analysis. Continuous variables are presented as
eans and standard deviations. Categorical variables are
resented as frequencies with percentages. For the analysis
f patient characteristic differences, Wilcoxon rank-sum
ests were used for continuous measures and Fisher exact
ests were used for categorical variables. For intra-group
omparisons, Wilcoxon signed-rank tests, nonparametric
nalog of the paired t test, were used to compare differences
ithin groups for continuous variables measured at baseline
nd after short-term (45 min) and 6 weeks of CPAP. For
nter-group comparisons, baseline values and differences in
ercent changes over time for continuous variables were
ompared between groups by Wilcoxon rank-sum tests. A p
alue of 0.05 was considered a statistically significant
ifference. Statistical calculations were carried out using
AS software (version 9.1.3, SAS Institute, Inc., Cary,
orth Carolina).
esults
atient characteristics. Thirteen HF patients were prospec-
tate Positron Emission Tomography Acquisition
ant;
ption.Ace
const
consumively enrolled in the study between April 2004 and July 2005.
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January 30, 2007:450–8 Effects of CPAP on Myocardial Energeticsne patient withdrew from the study before the baseline
nvestigations could be completed. Therefore, 12 patients
ompleted the study protocol.
The baseline characteristics of the patients are shown in
able 1. Seven patients were diagnosed as having OSA (group
), and 5 patients without OSA were considered control
atients (group II). Baseline characteristics were similar be-
ween groups. Three of 7 patients in group I (with OSA) had
n ischemic etiology, compared with 4 of 5 patients in group II
control patients) (p  NS). All patients in both groups were
eceiving a beta-blocker and either an angiotensin-converting
nzyme inhibitor or angiotensin receptor blocker drug therapy.
ll patients were clinically stable, with no change in their
edication regime during the follow-up period.
Continuous positive airway pressure was administrated at
mean of 10.6  1.6 cm H2O for 6.2  1.2 h per night to
roup I (with OSA) during the study period.
hort-term effects of CPAP therapy. Heart rate and blood
ressure (BP) were similar at rest and during short-term
PAP administration (Table 2). Short-term CPAP adminis-
ration tended to reduce SVI (p  0.063) and reduced LVEF
p  0.016). Myocardial oxidative metabolism was signifi-
antly reduced by short-term CPAP administration (kmono:
.047  0.012 to 0.041  0.014 min1, p  0.031) (Fig. 2).
s a result, there was no significant change in the WMI from
est to short-term CPAP administration (7.13 2.82 106 to
.40  2.68  106 mm Hg·ml/m2, p  NS) (Fig. 2).
onger-term effects of nocturnal CPAP therapy. There
ere no significant differences in baseline SVI, LVEF, LV
atient Characteristics
Table 1 Patient Characteristics
Age (yrs) Gender BMI Etiology HT
Group I
(with OSA)
1 57 M 36.0 Ischemic 
2 79 M 40.7 Nonischemic 
3 46 M 42.9 Nonischemic 
4 68 M 24.3 Ischemic 
5 51 M 40.1 Nonischemic 
6 55 M 35.8 Nonischemic 
7 70 M 35.5 Ischemic 
Mean  SD 61.0 11.7 36.5 6.1
Group II
(control)
1 78 M 27.3 Ischemic 
2 56 M 29.9 Ischemic 
3 59 M 26.9 Ischemic 
4 56 M 29.7 Ischemic 
5 59 M 37.9 Nonischemic 
Mean  SD 61.6 9.3 30.3 4.4
he Epworth Sleepiness Scale ranges from 0 to 24, with scores of 10 or higher indicating excessiv
quare of the height in meters; †p  0.019.
ACEI  angiotensin-converting enzyme inhibitor; AHI  apnea-hypopnea index; ARB  angioten
ypertension; LVEF  left ventricular ejection fraction; NYHA  New York Heart Association; OSAxidative metabolism, or WMI between the 2 groups. vHeart rate and BP were similar at baseline and after 6
eeks of nocturnal CPAP therapy in both groups (Table
). There was a slight increase in the body weight in the
SA group, but this was not statistically significant
group I [with OSA]: 103.7  24.9 kg to 106.3  27.7
g, p  NS; group II (control patients): 90.8  8.8 kg to
0.6  9.4 kg, p  NS]. For the OSA group, there was a
ide standard deviation in weight, with no consistent direc-
ional change. Also, there was also no clinical deterioration.
he slight difference in weight was thus likely due to variation
n the measurement.
Longer term (6 weeks) nocturnal CPAP therapy abol-
shed OSA and improved LVEF (p  0.031) in group I
with OSA). Furthermore, longer term CPAP therapy
NYHA
Functional
Class LVEF* (%)
Epworth
Scale AHI Treatment
2 36 6 81.1 ARB,BB,DIU
3 23 3 22.2 ACEI,BB,DIU
3 23 0 45 ACEI,BB,DIG,DIU
2 33 8 18 ARB,BB,DIU
2 37 14 52.5 ACEI,BB,DIU
2 30 4 29 ARB,BB,DIG,DIU
2 29 3 15.5 ACEI,BB,DIU
2.3 0.5 30.7 4.9% 5.4 4.5 37.6 23.6†
3 25 5 0.9 ACEI,BB,DIG,DIU
2 33 4 7.3 ARB,BB,DIG,DIU
2 22 4 0.3 ACEI,BB,DIU
2 32 7 3.2 ACEI,BB
2 23 4 2.8 ARB,BB
2.2 0.5 27.0 5.1% 4.8 1.3 2.9 2.7
me sleepiness. *LVEF by radionuclide angiography, BMI is the weight in kilograms divided by the
eptor blocker; BB  beta-blocker; BMI  body mass index; DIG  digoxin; DIU  diuretic; HTN 
ructive sleep apnea.
ffects of Short-Term CPAP Application
Table 2 Effects of Short-Term CPAP Application
Measurements
Group I (With OSA) (n  7)
Rest Short-Term CPAP
Heart rate, beats/min 59.8 7.0 57.3 7.5
SBP, mm Hg 141.0 19.9 143.1 15.1
SVI, ml/m2 37.2 8.3 34.3 8.1*
LVEF (%) 38.4 3.3 34.8 5.0†
kmono, min
1 0.047 0.012 0.041 0.014§‡
WMI, mm Hg·ml/m2 7.13 2.82 106 7.40 2.68 106
alues are mean SD. *p 0.063 comparison of rest to short-term CPAP application; †p 0.016
omparison of rest to short-term CPAP application; ‡p  0.031 comparison of rest to short-term
PAP application.N
e daytiCPAP  continuous positive airway pressure; SBP  systolic blood pressure; SVI  stroke
olume index; WMI  work metabolic index; other abbreviations as in Table 1
t
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Effects of CPAP on Myocardial Energetics January 30, 2007:450–8ended to decrease daytime LV oxidative metabolism
kmono: 0.047  0.012 to 0.040  0.008 min
1, p 
.078) while maintaining SVI (p  NS) (Table 3 and
ig. 3). As a result, longer-term CPAP therapy signifi-
antly improved the WMI (7.13  2.82 106 mm
g·ml/m2 to 8.17  3.06  106 mm Hg·ml/m2, p 
.031) (Fig. 3).
In group II (control group), there were no significant
hanges in SVI, LVEF, LV oxidative metabolism (0.039 
.007/min to 0.036  0.007/min, p  NS), or WMI (8.24
1.90  106 to 7.96  2.36  106 mm Hg·ml/m2, p 
S) from baseline to follow-up.
There was a significant improvement in the percent
hange of WMI in group I (with OSA) after 6 weeks
f CPAP therapy compared with group II (control
roup) (15.9  12.8% vs. 4.1  15.5%, p  0.044)
Fig. 4).
Figure 2 Effects of Short-Term CPAP Application
Stroke volume index, myocardial oxidative metabolism (kmono), and work metabolic
during short-term continuous positive airway pressure (CPAP) administration. *p 
ffects of 6 Weeks of Nocturnal CPAP Therapy
Table 3 Effects of 6 Weeks of Nocturnal CPAP Therapy
Measurements
Group I (With OSA) (n  7)
Baseline 6
Heart rate, beats/min 59.8 7.0 58.0
SBP, mm Hg 141.0 19.9 141.0
Weight, kg 103.7 24.9 106.3
SVI, ml/m2 37.2 8.3 37.6
LVEF (%) 38.4 3.3 43.4
kmono, min
1 0.047 0.012 0.040
WMI, mm Hg·ml/m2 7.13 2.82 106 8.17
alues aremean SD. *p 0.031 comparison of baseline to 6 weeks within group I; †p 0.078 co
ver time between group I and group II.
Abbreviations as in Tables 1 and 2.iscussion
n patients with OSA and HF, short-term CPAP ad-
inistration decreased oxidative metabolism, tended to
ecrease SVI and, as a result, did not alter cardiac
fficiency. However, longer term nocturnal CPAP led to
mproved LV systolic function while tending to reduce
V oxidative metabolism, thereby significantly improving
ardiac efficiency and demonstrating an energy-sparing
ffect.
F therapies. Most pharmacologic agents that are ben-
ficial for HF have at least 2 common characteristics.
irst, these agents improve cardiac function without
ncreasing MVO2 (17,23). Heart failure is an energy-
epleted state, and the improved survival with beta-
locker and vasodilator therapy relates in part to the
nergy-sparing effects of these agents (5,23). Inotropic
(WMI) at rest and
, †p  0.063 (trend). LV  left ventricular.
Group II (Control) (n  5)
s Baseline 6 Weeks
59.6 12.1 55.3 6.0
129.2 24.8 120.9 24.7
90.8 8.8 90.6 9.4
42.4 8.8 42.0 8.3
42.8 6.3 43.5 8.1
† 0.039 0.007 0.036 0.008
 106*‡ 8.24 1.90 106 7.96 2.36 106
on of baseline to 6 weeks within group I; ‡p 0.044 comparison of differences in percent changesindex
0.031Week
7.8
17.8
27.7
7.3
4.8*
0.008
3.06
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January 30, 2007:450–8 Effects of CPAP on Myocardial Energeticsedications, on the other hand, improve performance at
he expense of increasing MVO2. Many of these agents
ave detrimental effects and increase mortality rates
24,25). The discordance between improved LV perfor-
ance and increased mortality may result from these
gents’ detrimental cardiac energetic effects (17,23). Sec-
nd, most beneficial agents act by blocking neurohor-
onal activation.
However, less is known about the mechanical therapies
or HF, such as CPAP therapy, and whether these therapies
lso have a beneficial effect on cardiac metabolism and
fficiency (and thus cardiac energetics).
ffects of CPAP Therapy. EFFECTS OF SHORT-TERM
PAP ADMINISTRATION. Short-term CPAP administra-
ion prevents recurrent hypopnea and associated hypoxia,
educes BP and HR, and reduces sympathetic nervous
ystem activity (19,26). Left ventricular preload and
Figure 3 Effects of 6 Weeks of CPAP on Oxidative Metabolism
(A) kmono at baseline and after 6 weeks of CPAP therapy. *p  0.078 (trend); (B)
and after 6 weeks of CPAP therapy. *p  0.031. OSA  obstructive sleep apnea;fterload fall through the generation of positive intratho- Sacic pressure (27). This reduces cardiac output in the
ormal heart by decreasing venous return and LV filling
2,27). In HF, the response of SV and cardiac output to
hort-term CPAP administration has been variable
27–30).
In the current study, SVI tended to decrease without
hange in BP during short-term CPAP administration.
his may have related to a reduction in venous return.
lternatively, the acute decrease in SVI may be related to
educed work of ventilation. It is known that hyperventila-
ion models significantly increase cardiac output (31). Use of
PAP may have the opposite effect, reducing demand on
he LV. The decrease in SVI would be expected to result in
reduction in metabolic demand. Indeed, short-term
PAP administration also acutely reduced myocardial oxi-
ative metabolism. However, external cardiac efficiency was
ot altered with short-term CPAP administration, as both
on Efficiency
t baseline
abbreviations as in Figure 2.and
WMI a
otherVI and oxidative metabolism were decreased.
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Effects of CPAP on Myocardial Energetics January 30, 2007:450–8ONGER-TERM EFFECTS OF CPAP THERAPY. In patients
ith OSA and HF, previous studies have demonstrated an
mprovement in LV systolic function after 1 to 3 months of
PAP therapy (10–12). Recently, a randomized study by
aneko et al. (10) demonstrated an improvement in LVEF
rom 25% to 34% in 12 patients receiving 1 month of CPAP
herapy (10). The current study is consistent with these
revious investigations (10–12) and demonstrated a signif-
cant improvement in LVEF after 6 weeks of nocturnal
PAP therapy in patients with OSA and HF.
otential energy-sparing effects of CPAP. Although the
eported hemodynamic responses to CPAP therapy have
een variable (27–30), one important consistent effect has
een the reduction of LV transmural pressure (27). This,
ombined with CPAP’s effects of eliminating hypoxia and
educing sympathetic activity, has the potential to reduce
yocardial energy demand and MVO2. Because HF is
nown to be an energy-depleted state (5), CPAP therapy
ould permit repletion of energy stores and more efficient
nergy transduction to useful work, which is constantly
emanded of the failing heart.
Kaye et al. (28) demonstrated a 20% reduction in MVO2
fter 10 min of CPAP administration, measured via coro-
ary sinus catheterization in patients with HF but without
SA (28). The authors suggested that this reflects an acute
eneficial effect of CPAP administration on cardiac ener-
etics. However, a 15% reduction in stroke work was also
oted. In this acute setting, reduced MVO2 with CPAP
dministration may have simply reflected the reduction in
troke-work and, therefore, no definite benefit on energetics
an be inferred. Similar results were observed in the current
tudy, with acute reductions in oxidative metabolism and
VI during short-term CPAP and, as a result, no change in
fficiency; the difference was that our patients with HF also
ad OSA and that we also evaluated longer term CPAP
Figure 4 Percent Change in Myocardial Efficiency
Percent change of WMI from baseline to 6 weeks after CPAP therapy in group I
(with obstructive sleep apnea [OSA]) and in group II (control). *p  0.044
versus group II (control). Abbreviations as in Figure 2.herapy. bIt is more difficult to predict the response of myocardial
etabolism with longer term CPAP therapy. It is known
hat 1 to 3 months of CPAP therapy in patients with HF
nd OSA increases LV function (10–12). If myocardial
xidative metabolism simply parallels SV or stroke work (as
bserved in our short-term results and by Kaye et al. (28)
egarding MVO2 and stroke-work changes), then myocar-
ial oxidative metabolism may be expected to increase over
ime, and no improvement in cardiac efficiency may occur.
uch a finding would suggest that CPAP therapy was of
imited benefit for daytime cardiac energetics, or might even
e detrimental to the energy depleted failing heart despite
n improvement in LV systolic function (5,23). On the
ontrary, this was not observed in the current study.
Bradley and Floras (2) have proposed that the favorable
ffects of CPAP therapy on LV systolic function and
ympathetic nervous system activity are similar to beta-
locker therapy. Beta-blocker therapy acutely reduces SV
nd MVO2, but chronically improves LV systolic function
ith reduced MVO2 and oxidative metabolism. As a result,
ardiac efficiency is improved (6,32). The present data show
similar pattern with acute reductions in oxidative metab-
lism and SVI, but after 6 weeks of nocturnal CPAP
herapy, there is reduced myocardial oxidative metabolism
ith improved cardiac efficiency in patients with OSA and
F. The mechanism for this beneficial effect is not known,
ut the response does appear similar to beta-blocker effects
2). As proposed for beta-blockade, over time the metabolic
enefit of CPAP therapy may allow repletion of energy
tores and permit redirection of energy utilization and gene
ranscription to repair cell injury and restore contractile
lements (6,32).
Because the patients in the current study were on beta-
locker therapy, the effect of CPAP is additive to the stable
eta-blocker therapy. Previous data from Mansfield et al.
11) showed that longer term CPAP improved LV systolic
unction in patients with OSA and HF, 79% of whom were
lready treated with a beta-blocker drug. This study also
upports that there is an additive effect of CPAP (11).
Longer term CPAP therapy has also been shown to
educe sympathetic nervous system activity in patients with
SA and HF (33). Such a reduction in sympathetic
unction may also contribute to the changes in myocardial
xidative metabolism observed in the current study. We did
ot observe a significant change in HR or BP. However, in
he study by Mansfield et al. (11), improvement in LV
unction was accompanied by a reduction of urinary norepi-
ephrine secretion without significant hemodynamic
hanges. This suggests that the sympathetic nervous system
ffects of CPAP may occur independent of changes in HR
r BP (possibly because of the concomitant beta-blocker
herapy as suggested by the authors). Such sympathetic
unction changes may directly affect the myocardium, but
his notion remains speculative and requires further study.
tudy limitations. The sample size of this study is small,
ut it is similar to previous physiologic studies that have
e
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10,33), as well as other metabolic studies in HF (34).
espite the small population size, beneficial therapeutic
ffects of CPAP therapy on myocardial energetics were
emonstrated. The current study supports the need for
arger randomized controlled studies to evaluate the effects
nd benefits of longer term CPAP therapy. Such a random-
zed control trial has now been initiated. Results of this
tudy will not be available for 3 to 4 years.
The present study included patients with ischemic and
on-ischemic etiologies of HF. The response of myocardial
nergetics to CPAP therapy may differ depending on the
F etiology. However, a previous study (10) demonstrated
similar improvement in LV function in ischemic and
on-ischemic cardiomyopathy with longer term CPAP
herapy. Nevertheless, further studies in these specific sub-
opulations are needed.
The present study included only male subjects, in part
eflecting the available population. Although the mecha-
isms of CPAP effects may be similar, results cannot be
irectly applied to women. This area requires further study.
onclusions. On the basis of the results of this pilot study,
hort-term CPAP administration appears to decrease oxi-
ative metabolism and tends to decrease SVI. As a result, it
oes not appear to alter myocardial efficiency. Longer term
PAP treatment (6 weeks), on the other hand, may lead to
n improvement in LV systolic function and a trend to
eduction in oxidative metabolism with a significant im-
rovement in myocardial efficiency. This may indicate an
nergy-sparing effect of nocturnal CPAP therapy. The
ardiac energetic effects may contribute to the clinical
enefits observed with CPAP therapy in patients with
bstructive sleep apnea and HF. Larger randomized studies
re warranted.
cknowledgments
he authors thank Karen Hay, May Aung, CNMT, Kim-
erley Gardner, CNMT, Kathy Menchini, Deborah Gau-
hier, RN, AnneMarie LaRue, RN, Michaela Garkisch,
N, Marg Fraser, RN, Debbie Swihart, Samantha Mason,
Sc, Paul Coleta, BEng, and Sherri Nipius for their support
f this study.
eprint requests and correspondence: Dr. Rob S. B. Beanlands,
niversity of Ottawa Heart Institute, 40 Ruskin Street, Ottawa,
ntario K1Y 4W7, Canada. E-mail: rbeanlands@ottawaheart.ca.
EFERENCES
1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007–18.
2. Bradley TD, Floras JS. Sleep apnea and heart failure: part I: obstruc-
tive sleep apnea. Circulation 2003;107:1671–8.
3. Javaheri S, Parker TJ, Liming JD, et al. Sleep apnea in 81
ambulatory male patients with stable heart failure. Types and their
prevalences, consequences, and presentations. Circulation 1998;97:
2154 –9.4. Malhotra A, White DP. Obstructive sleep apnoea. Lancet 2002;360:
237–45.5. Katz AM. Potential deleterious effects of inotropic agents in the
therapy of chronic heart failure. Circulation 1986;73:III184–90.
6. Beanlands RS, Nahmias C, Gordon E, et al. The effects of beta(1)-
blockade on oxidative metabolism and the metabolic cost of ventricular
work in patients with left ventricular dysfunction: a double-blind,
placebo-controlled, positron-emission tomography study. Circulation
2000;102:2070–5.
7. Bing R, Hammond M, Handleman J, et al. The measurement of
coronary blood flow, oxygen consumption and efficiency of the left
ventricle in man. Am Heart J 1949;38:1–24.
8. Kim IS, Izawa H, Sobue T, et al. Prognostic value of mechanical
efficiency in ambulatory patients with idiopathic dilated cardiomyop-
athy in sinus rhythm. J Am Coll Cardiol 2002;39:1264–8.
9. Narkiewicz K, Kato M, Phillips BG, Pesek CA, Davison DE, Somers
VK. Nocturnal continuous positive airway pressure decreases daytime
sympathetic traffic in obstructive sleep apnea. Circulation 1999;100:
2332–5.
0. Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous
positive airway pressure in patients with heart failure and obstructive
sleep apnea. N Engl J Med 2003;348:1233–41.
1. Mansfield DR, Gollogly NC, Kaye DM, Richardson M, Bergin P,
Naughton MT. Controlled trial of continuous positive airway pressure
in obstructive sleep apnea and heart failure. Am J Respir Crit Care
Med 2004;169:361–6.
2. Malone S, Liu PP, Holloway R, Rutherford R, Xie A, Bradley TD.
Obstructive sleep apnoea in patients with dilated cardiomyopathy:
effects of continuous positive airway pressure. Lancet 1991;338:
1480–4.
3. Armbrecht JJ, Buxton DB, Brunken RC, Phelps ME, Schelbert HR.
Regional myocardial oxygen consumption determined noninvasively in
humans with [1-11C]acetate and dynamic positron tomography.
Circulation 1989;80:863–72.
4. Brown M, Marshall DR, Sobel BE, Bergmann SR. Delineation of
myocardial oxygen utilization with carbon-11-labeled acetate. Circu-
lation 1987;76:687–96.
5. Stolen KQ, Kemppainen J, Ukkonen H, et al. Exercise training
improves biventricular oxidative metabolism and left ventricular effi-
ciency in patients with dilated cardiomyopathy. J Am Coll Cardiol
2003;41:460–7.
6. Ukkonen H, Beanlands RS, Burwash IG, et al. Effect of cardiac
resynchronization on myocardial efficiency and regional oxidative
metabolism. Circulation 2003;107:28–31.
7. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on
morbidity and mortality in patients with chronic heart failure. U.S.
Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349–55.
8. Kryger MH. Management of obstructive sleep apnea-hypopnea syn-
drome: overview. In: Kryger MH, Roth T, Dement WC, eds.
Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia: W.B.
Saunders Company, 2000:940–54.
9. Butler GC, Naughton MT, Rahman MA, Bradley TD, Floras JS.
Continuous positive airway pressure increases heart rate variability in
congestive heart failure. J Am Coll Cardiol 1995;25:672–9.
0. Rechtschaffen A, Kales A, editors. A Manual of Standardized Termi-
nology, Techniques and Scoring System for Sleep Stages of Human
Subjects. Los Angeles, CA: UCLA, Brain Information Service/Brain
Research, University of California, 1968.
1. Burwash IG, Forbes AD, Sadahiro M, et al. Echocardiographic
volume flow and stenosis severity measures with changing flow rate in
aortic stenosis. Am J Physiol 1993;265:H1734–43.
2. Yoshinaga K, Katoh C, Beanlands RS, et al. Reduced oxidative
metabolic response in dysfunctional myocardium with preserved glu-
cose metabolism but with impaired contractile reserve. J Nucl Med
2004;45:1885–91.
3. Katz AM. Changing strategies in the management of heart failure.
J Am Coll Cardiol 1989;13:513–23.
4. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in
severe heart failure. Lancet 1990;336:1–6.
5. Packer M, Medina N, Yakushak M. Hemodynamic and clinical
limitations of long-term inotropic therapy with amrinone in patients
with severe chronic heart failure. Circulation 1984;70:1038–47.
6. Brooks D, Horner RL, Kozar LF, Render-Teixeira CL,
Phillipson EA. Obstructive sleep apnea as a cause of systemic
22
2
3
3
3
3
3
458 Yoshinaga et al. JACC Vol. 49, No. 4, 2007
Effects of CPAP on Myocardial Energetics January 30, 2007:450–8hypertension. Evidence from a canine model. J Clin Invest
1997;99:106 –9.
7. Naughton MT, Rahman MA, Hara K, Floras JS, Bradley TD. Effect
of continuous positive airway pressure on intrathoracic and left
ventricular transmural pressures in patients with congestive heart
failure. Circulation 1995;91:1725–31.
8. Kaye DM, Mansfield D, Naughton MT. Continuous positive airway
pressure decreases myocardial oxygen consumption in heart failure.
Clin Sci (Lond) 2004;106:599–603.
9. Bradley TD, Holloway RM, McLaughlin PR, Ross BL, Walters J,
Liu PP. Cardiac output response to continuous positive airway
pressure in congestive heart failure. Am Rev Respir Dis 1992;145:
377– 82.
0. Pinsky MR, Matuschak GM, Klain M. Determinants of cardiac
augmentation by elevations in intrathoracic pressure. J Appl Physiol
1985;58:1189–98.1. Robertson CH Jr., Pagel MA, Johnson RL Jr. The distribution of
blood flow, oxygen consumption, and work output among the respi-
ratory muscles during unobstructed hyperventilation. J Clin Invest
1977;59:43–50.
2. Eichhorn EJ, Bedotto JB, Malloy CR, et al. Effect of beta-adrenergic
blockade on myocardial function and energetics in congestive heart failure.
Improvements in hemodynamic, contractile, and diastolic performance
with bucindolol. Circulation 1990;82:473–83.
3. Usui K, Bradley TD, Spaak J, et al. Inhibition of awake sympathetic
nerve activity of heart failure patients with obstructive sleep apnea by
nocturnal continuous positive airway pressure. J Am Coll Cardiol
2005;45:2008–11.
4. Wallhaus TR, Taylor M, DeGrado TR, et al. Myocardial free fatty
acid and glucose use after carvedilol treatment in patients with
congestive heart failure. Circulation 2001;103:2441–6.
